| IPO Company Profile |
| SEC Filings | Peer IPO Companies |
| Phytera, Inc. |
| 377 Plantation Street, Worcester, MA 01605 * (508) 792-6800 |
| The company is an international biopharmaceutical company engaged in identifying and optimizing novel chemical lead structures through its Combinatorial Drug Discovery Program. |
| Manager | Tier | Phone |
| SG Cowen | Lead Manager | |
| BancBoston Robertson Stephens | Co-manager | (415) 989-8500 |
| NASNTL: | PHYT | Service: | SIC 8731 | |
| Type of Shares: | Common Shares | Filing Date: | 10/28/98 | |
| U.S. Shares Filed: | 2,500,000 | Filing Range: | $12.00 - $14.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $32,500,000 | |
| Primary Shares: | 2,500,000 | Expenses: | - | |
| Secondary Shares: | 0 | Post-IPO Shares: | ||
| Employees: | 75 |
| Issuer's Law Firm: | Palmer & Dodge |
| Bank's Law Firm: | Brown & Wood |
| Registrar/Transfer Agent: | American Stock Transfer & Trust Co |
| Auditor: | Arthur Andersen |
Dollar amounts in U.S. millions except for per share data | |||||
| 9 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Audited Income | Balance Sheet | ||
| 12/31/97 | 9/30/98 | 9/30/97 | 9/30/98 | ||
| Revenue: | $1.05 | $1.10 | $0.73 | Assets: | $9.31 |
| Net Income: | -$9.75 | -$6.59 | -$7.66 | Curr Assets: | $7.28 |
| EPS: | $1.42 | Liabilities: | $4.42 | ||
| Prior EPS: | Curr Liab: | $2.23 | |||
| Cash Flow/Oper: | -$7.40 | -$4.94 | $5.09 | Equity: | $4.89 |
| Cash Flow/Fin: | $0.34 | $8.47 | $0.19 | Cash: | $6.99 |
| Cash Flow/Inv: | $6.39 | -$0.98 | $4.21 | Working Cap: | $5.05 |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to fund research and product development programs, to repay indebtedness and for general corporate purposes. |